Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flupentixol-Melitracen + Lansoprazole in GERD
NCT06945237Completed
- Sponsor
- Renji Hospital
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Flupentixol-Melitracen + Lansoprazole with Placebo + Lansoprazole (2 arms). Primary endpoint: GERD questionnaire at 12 weeks. Started Apr 2025; status: completed.
02
Drugs
flupentixol + melitracen
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06945237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945237.